Back to Journals » Transplant Research and Risk Management » Volume 6

Next-generation calcineurin inhibitors in development for the prevention of organ rejection

Authors Gheith O, Al-Otaibi T, Mansour H

Received 16 October 2013

Accepted for publication 12 December 2013

Published 25 March 2014 Volume 2014:6 Pages 23—30

DOI https://doi.org/10.2147/TRRM.S35875

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Osama Gheith, Torki Al-Otaibi, Hany Mansour

Department of Nephrology, Hamed Al-Essa Organ Transplant Center, Ibn Sina Hospital, Shuwaikh, Kuwait

Abstract: Calcineurin inhibitors (CNIs) remain the cornerstone of immunosuppression after renal transplantation despite their adverse effects. Some CNIs have well known negative impacts on the cardiovascular system, including hypertension, hyperlipidemia, new onset diabetes after transplantation (NODAT), neurotoxicity, hypertrichosis, and nephrotoxicity. Many clinical trials dealing with CNI avoidance or elimination were associated with higher risk of rejection of the transplanted organ. New generation CNIs are concerned with modifying CNI molecules so that they become more potent and are suitable for patients with suboptimal adherence with less adverse effects. In this review, we address these issues.

Keywords: calcineurin inhibitors, organ transplant, rejection

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]